While ESAs can be beneficial, they are not without risks. The use of ESAs in cancer patients has been associated with increased risks of thromboembolic events, such as blood clots, strokes, and heart attacks. Additionally, there is some evidence to suggest that ESAs might promote tumor growth or reduce survival rates in certain types of cancer. Therefore, the use of ESAs must be carefully considered and monitored by healthcare providers.
